{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:46:04Z","timestamp":1761896764704},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:p>Hypertrophic cardiomyopathy (HCM) is an inherited disease characterized by unexplained left ventricular hypertrophy. Although it is estimated to affect 1 out of 500 people, the HCM gene carrier prevalence is much more common, probably as high as 1 in 200 people. Most affected individuals have a normal life expectancy, whereas some patients may develop sudden cardiac death or end-stage heart failure. Despite significant developments in the treatment of HCM with surgical, interventional, and device-based procedures, the main focus of current pharmacological therapy has not evolved from the basic objectives of relief of symptoms and improvement in functional capacity. To date, no medical treatment has been shown to prolong survival or reduce the risk of sudden cardiac death. In recent decades, research focus in HCM has shifted to identify the treatments which are able to alter the natural pathophysiological process of this disease. This article reviews the currently recommended and frequently used medications (beta-blockers, nondihydropyridine calcium channel blockers, and disopyramide) and emerging pharmacological treatment options in the management of HCM. The mechanism of action and latest clinical trials of the novel agents are discussed in greater detail.<\/jats:p>","DOI":"10.1097\/crd.0000000000000211","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T02:31:43Z","timestamp":1525919503000},"page":"239-244","source":"Crossref","is-referenced-by-count":12,"title":["Novel Pharmacotherapy in Hypertrophic Cardiomyopathy"],"prefix":"10.1097","volume":"26","author":[{"given":"Gabriela","family":"Andries","sequence":"first","affiliation":[{"name":"Department of Medicine, New York Medical College at Westchester Medical Center, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srikanth","family":"Yandrapalli","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College at Westchester Medical Center, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srihari S.","family":"Naidu","sequence":"additional","affiliation":[{"name":"Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio A.","family":"Panza","sequence":"additional","affiliation":[{"name":"Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/j.jacc.2011.06.011","article-title":"2011 ACCF\/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.","volume":"58","author":"Gersh","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy.","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jacc.2012.02.068","article-title":"Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives.","volume":"60","author":"Maron","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0735-1097(93)90054-5","article-title":"Coexistence of sudden cardiac death and end-stage heart failure in familial hypertrophic cardiomyopathy.","volume":"22","author":"Hecht","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1161\/CIRCULATIONAHA.110.950089","article-title":"Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute.","volume":"122","author":"Force","year":"2010","journal-title":"Circulation"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/heartjnl-2015-308343","article-title":"Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial.","volume":"102","author":"Axelsson","year":"2016","journal-title":"Heart"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2017.02.008","article-title":"The design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial.","volume":"187","author":"Ho","year":"2017","journal-title":"Am Heart J"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","article-title":"Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy.","volume":"122","author":"Abozguia","year":"2010","journal-title":"Circulation"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"e004124","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124","article-title":"Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study.","volume":"11","author":"Olivotto","year":"2018","journal-title":"Circ Heart Fail"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"e002764","DOI":"10.1161\/CIRCHEARTFAILURE.115.002764","article-title":"Novel approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: the impact of Late Sodium Current Inhibition on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) Trial.","volume":"9","author":"Olivotto","year":"2016","journal-title":"Circ Heart Fail"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jchf.2014.08.003","article-title":"Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression.","volume":"3","author":"Ho","year":"2015","journal-title":"JACC Heart Fail"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4103\/1995-705X.201784","article-title":"Statin induced regression of cardiomyopathy trial: a randomized, placebo-controlled double-blind trial.","volume":"17","author":"Hersi","year":"2016","journal-title":"Heart Views"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/01.RES.0000177090.07296.ac","article-title":"Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy.","volume":"97","author":"Senthil","year":"2005","journal-title":"Circ Res"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCRESAHA.117.312647","article-title":"Hypertrophy Regression With N-Acetylcysteine in Hypertrophic Cardiomyopathy (HALT-HCM): a randomized, placebo-controlled, double-blind pilot study.","volume":"122","author":"Marian","year":"2018","journal-title":"Circ Res"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.","volume":"45","author":"Sherrid","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","article-title":"Disopyramide: treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with \u03b2-blockade or verapamil.","volume":"6","author":"Sherrid","year":"2013","journal-title":"Circ Heart Fail"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/j.crvasa.2015.02.003","article-title":"Medical treatment of hypertrophic cardiomyopathy \u2013 what do we know about it today?","volume":"57","author":"Gregor","year":"2015","journal-title":"Cor Et Vasa"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).","volume":"35","year":"2014","journal-title":"Eur Heart J"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1161\/01.CIR.97.1.41","article-title":"Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy.","volume":"97","author":"Sherrid","year":"1998","journal-title":"Circulation"},{"key":"R27-20230903","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/hrt.48.3.204","article-title":"Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs.","volume":"48","author":"Alvares","year":"1982","journal-title":"Br Heart J"},{"key":"R28-20230903","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1161\/01.CIR.60.6.1208","article-title":"Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status.","volume":"60","author":"Rosing","year":"1979","journal-title":"Circulation"},{"key":"R29-20230903","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1172\/JCI115061","article-title":"Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole.","volume":"87","author":"Gwathmey","year":"1991","journal-title":"J Clin Invest"},{"key":"R30-20230903","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1161\/01.CIR.96.5.1520","article-title":"Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy.","volume":"96","author":"Hamada","year":"1997","journal-title":"Circulation"},{"key":"R31-20230903","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1253\/jcj.65.531","article-title":"Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy.","volume":"65","author":"Hamada","year":"2001","journal-title":"Jpn Circ J"},{"key":"R32-20230903","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/phar.1664","article-title":"Disopyramide for hypertrophic cardiomyopathy: a pragmatic reappraisal of an old drug.","volume":"35","author":"Verlinden","year":"2015","journal-title":"Pharmacotherapy"},{"key":"R33-20230903","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/01.CIR.103.6.789","article-title":"Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy.","volume":"103","author":"Lim","year":"2001","journal-title":"Circulation"},{"key":"R34-20230903","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/01.CIR.0000121426.43044.2B","article-title":"Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy.","volume":"109","author":"Tsybouleva","year":"2004","journal-title":"Circulation"},{"key":"R35-20230903","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.amjcard.2005.07.065","article-title":"Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy.","volume":"96","author":"Araujo","year":"2005","journal-title":"Am J Cardiol"},{"key":"R36-20230903","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2353\/jmoldx.2009.080082","article-title":"The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study.","volume":"11","author":"Penicka","year":"2009","journal-title":"J Mol Diagn"},{"key":"R37-20230903","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1536\/ihj.48.715","article-title":"A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an Angiotensin II receptor blocker.","volume":"48","author":"Yamazaki","year":"2007","journal-title":"Int Heart J"},{"key":"R38-20230903","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jchf.2013.09.001","article-title":"Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy.","volume":"1","author":"Shimada","year":"2013","journal-title":"JACC Heart Fail"},{"key":"R39-20230903","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-8587(14)70241-4","article-title":"Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial.","volume":"3","author":"Axelsson","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R40-20230903","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/S0735-1097(02)03009-7","article-title":"Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy.","volume":"41","author":"Crilley","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R41-20230903","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1161\/01.CIR.97.25.2536","article-title":"31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy.","volume":"97","author":"Jung","year":"1998","journal-title":"Circulation"},{"key":"R42-20230903","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0168-9525(03)00081-7","article-title":"Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion.","volume":"19","author":"Ashrafian","year":"2003","journal-title":"Trends Genet"},{"key":"R43-20230903","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1161\/CIRCULATIONAHA.110.981464","article-title":"Perhexiline and hypertrophic cardiomyopathy: a new horizon for metabolic modulation.","volume":"122","author":"Horowitz","year":"2010","journal-title":"Circulation"},{"key":"R44-20230903","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1527-3466.2007.00006.x","article-title":"Perhexiline.","volume":"25","author":"Ashrafian","year":"2007","journal-title":"Cardiovasc Drug Rev"},{"key":"R45-20230903","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.3390\/diseases5020014","article-title":"Targeting metabolic modulation and mitochondrial dysfunction in the treatment of heart failure.","volume":"5","author":"Steggall","year":"2017","journal-title":"Diseases"},{"key":"R46-20230903","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00005344-199503000-00018","article-title":"Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate.","volume":"25","author":"Jeffrey","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"R47-20230903","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1039\/C4MB00594E","article-title":"Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy.","volume":"11","author":"Gehmlich","year":"2015","journal-title":"Mol Biosyst"},{"key":"R48-20230903","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","article-title":"Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy.","volume":"127","author":"Coppini","year":"2013","journal-title":"Circulation"},{"key":"R49-20230903","doi-asserted-by":"crossref","first-page":"e003565","DOI":"10.1161\/CIRCHEARTFAILURE.116.003565","article-title":"Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy.","volume":"10","author":"Coppini","year":"2017","journal-title":"Circ Heart Fail"},{"key":"R50-20230903","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.jacc.2016.07.758","article-title":"Ranolazine for treatment of angina or dyspnea in hypertrophic cardiomyopathy patients (RHYME).","volume":"68","author":"Gentry","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R51-20230903","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.cjca.2017.07.007","article-title":"New developments in hypertrophic cardiomyopathy.","volume":"33","author":"Cooper","year":"2017","journal-title":"Can J Cardiol"},{"key":"R52-20230903","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.bpj.2014.02.011","article-title":"Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases.","volume":"106","author":"Spudich","year":"2014","journal-title":"Biophys J"},{"key":"R53-20230903","doi-asserted-by":"crossref","first-page":"12607","DOI":"10.1073\/pnas.1309493110","article-title":"Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human \u03b2-cardiac myosin motor function.","volume":"110","author":"Sommese","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"R54-20230903","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice.","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"R55-20230903","doi-asserted-by":"crossref","first-page":"e0168407","DOI":"10.1371\/journal.pone.0168407","article-title":"A small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy.","volume":"11","author":"Stern","year":"2016","journal-title":"PLoS One"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00045415-201809000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T09:28:03Z","timestamp":1693733283000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-201809000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000211","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}